Use of the Cre/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an alpha1(I) G349C substitution. Variability in phenotype in BrtlIV mice - PubMed (original) (raw)
. 1999 Dec 31;274(53):37923-31.
doi: 10.1074/jbc.274.53.37923.
Affiliations
- PMID: 10608859
- DOI: 10.1074/jbc.274.53.37923
Free article
Use of the Cre/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an alpha1(I) G349C substitution. Variability in phenotype in BrtlIV mice
A Forlino et al. J Biol Chem. 1999.
Free article
Abstract
We utilized the Cre/lox recombination system to develop the first knock-in murine model for osteogenesis imperfecta (OI). The moderately severe OI phenotype was obtained from an alpha1(I) Gly(349) --> Cys substitution in type I collagen, reproducing the mutation in a type IV OI child. We introduced four single nucleotide (nt) changes into murine col1a1 exon 23: the disease causing G-->T transversion (nt 1546), an adjacent G-->T change (nt 1551) to generate a GUC ribozyme cleavage site, and two transversions (nt 1567 C-->A and nt 1569 C-->G) to cause a Leu --> Met substitution. We also introduced a 3.2-kilobase pair transcription/translation stop cassette in intron 22, flanked by directly repeating lox recombination sites. After homologous recombination in ES cells, two male chimeras were obtained. Chimeras were mated with transgenic females expressing Cre recombinase to remove the stop cassette from a portion of the progeny's cells. To generate mice with full expression of the Gly(349) --> Cys mutation, these offspring were then mated with wild-type females. Skeletal staining and bone histology of the F2 revealed a classical OI phenotype with deformity, fragility, osteoporosis and disorganized trabecular structure. We designate these mice BrtlIV (Brittle IV). BrtlIV mice have phenotypic variability ranging from perinatal lethality to long term survival with reproductive success. The phenotypic variability is not associated with differences in expression levels of the mutant allele in total RNA derived from tissue extracts. Expression of the mutant protein is also equivalent in different phenotypes. Thus, these mice are an excellent model for delineation of the modifying factors postulated to affect human OI phenotypes. In addition, we generated knock-in mice carrying an "intronic" inclusion by mating chimeras with wild-type females. Alternative splicing involving the stop cassette results in retention of non-collagenous sequences. These mice reproduce the lethal phenotype of similar human mutations and are designated BrtlII.
Similar articles
- Structure, stability and interactions of type I collagen with GLY349-CYS substitution in alpha 1(I) chain in a murine Osteogenesis Imperfecta model.
Kuznetsova NV, Forlino A, Cabral WA, Marini JC, Leikin S. Kuznetsova NV, et al. Matrix Biol. 2004 May;23(2):101-12. doi: 10.1016/j.matbio.2004.03.002. Matrix Biol. 2004. PMID: 15246109 - Osteogenesis imperfecta: prospects for molecular therapeutics.
Forlino A, Marini JC. Forlino A, et al. Mol Genet Metab. 2000 Sep-Oct;71(1-2):225-32. doi: 10.1006/mgme.2000.3039. Mol Genet Metab. 2000. PMID: 11001814 Review. - Dissecting the phenotypic variability of osteogenesis imperfecta.
Garibaldi N, Besio R, Dalgleish R, Villani S, Barnes AM, Marini JC, Forlino A. Garibaldi N, et al. Dis Model Mech. 2022 May 1;15(5):dmm049398. doi: 10.1242/dmm.049398. Epub 2022 May 16. Dis Model Mech. 2022. PMID: 35575034 Free PMC article. - Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans.
Marini JC, Forlino A, Cabral WA, Barnes AM, San Antonio JD, Milgrom S, Hyland JC, Körkkö J, Prockop DJ, De Paepe A, Coucke P, Symoens S, Glorieux FH, Roughley PJ, Lund AM, Kuurila-Svahn K, Hartikka H, Cohn DH, Krakow D, Mottes M, Schwarze U, Chen D, Yang K, Kuslich C, Troendle J, Dalgleish R, Byers PH. Marini JC, et al. Hum Mutat. 2007 Mar;28(3):209-21. doi: 10.1002/humu.20429. Hum Mutat. 2007. PMID: 17078022 Free PMC article. Review.
Cited by
- Update on the Genetics of Osteogenesis Imperfecta.
Jovanovic M, Marini JC. Jovanovic M, et al. Calcif Tissue Int. 2024 Aug 11. doi: 10.1007/s00223-024-01266-5. Online ahead of print. Calcif Tissue Int. 2024. PMID: 39127989 Review. - Sclerostin antibody enhances implant osseointegration in bone with Col1a1 mutation.
Sung HH, Kwon HH, Stephan C, Reynolds SM, Dai Z, Van der Kraan PM, Caird MS, Blaney Davidson EN, Kozloff KM. Sung HH, et al. Bone. 2024 Sep;186:117167. doi: 10.1016/j.bone.2024.117167. Epub 2024 Jun 13. Bone. 2024. PMID: 38876270 Free PMC article. - Collagen mutation and age contribute to differential craniofacial phenotypes in mouse models of osteogenesis imperfecta.
Sung HH, Spresser WJ, Hoffmann JP, Dai Z, Van der Kraan PM, Caird MS, Davidson EB, Kozloff KM. Sung HH, et al. JBMR Plus. 2024 Jan 4;8(1):ziad004. doi: 10.1093/jbmrpl/ziad004. eCollection 2024 Jan. JBMR Plus. 2024. PMID: 38690127 Free PMC article. - Extra-Skeletal Manifestations in Osteogenesis Imperfecta Mouse Models.
Crawford TK, Lafaver BN, Phillips CL. Crawford TK, et al. Calcif Tissue Int. 2024 Apr 19. doi: 10.1007/s00223-024-01213-4. Online ahead of print. Calcif Tissue Int. 2024. PMID: 38641703 - CaMKII inhibition due to TRIC-B loss-of-function dysregulates SMAD signaling in osteogenesis imperfecta.
Besio R, Contento BM, Garibaldi N, Filibian M, Sonntag S, Shmerling D, Tonelli F, Biggiogera M, Brini M, Salmaso A, Jovanovic M, Marini JC, Rossi A, Forlino A. Besio R, et al. Matrix Biol. 2023 Jun;120:43-59. doi: 10.1016/j.matbio.2023.05.002. Epub 2023 May 11. Matrix Biol. 2023. PMID: 37178987 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous